Bifunctional molecules that recruit deubiquitinating enzymes to target proteins to remove ubiquitin

Entact Bio is pioneering a novel approach to drug development through its ENTAC™ (enhancement-targeting chimeras) technology, which focuses on enhancing protein function rather than inhibiting it. This innovative strategy aims to restore health by addressing critical proteins that may be in short supply, mislocalized within the cell, or exhibiting suboptimal activity. By utilizing small-molecule drugs that act as molecular matchmakers, ENTACs recruit specific deubiquitylases (DUBs) to target proteins, effectively enhancing their function. This method allows for the targeting of previously undruggable pathways and offers potential treatments for hard-to-treat genetic disorders and common complex diseases.

The Encompass™ platform is central to Entact Bio's operations, providing a comprehensive system for the efficient creation of ENTACs. This proprietary platform integrates advanced biological, chemical, and computational tools to identify suitable disease targets for ENTAC intervention, select optimal DUBs, and design specific ENTACs tailored to each target-DUB pair. By leveraging AI-driven target discovery and a detailed understanding of DUB biology, Entact Bio aims to expand the range of treatable diseases and enhance the therapeutic potential of its drug candidates.

United States

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

Entact Bio

Company Details